Oncogene 2008, 20: 6194–6206.CrossRef 30. Ohshima M, Yamaguchi Y, Kappert K, Micke P, Otsuka KG: bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts. Biochem Biophys Res Commun 2009, 381: 165–170.CrossRefPubMed 31. Cassina P, Pehar M, Vargas MR, Castellanos R, Barbeito AG, Estévez AG, Thompson JA, Beckman JS, Barbeito L: Astrocyte activation by fibroblast growth factor-1 and motor neuron

apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem 2005, 93: 38–46.CrossRefPubMed 32. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M, Berger W: Fibroblast growth factor receptor-mediated signals contribute to VS-4718 price the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008, 7: 3408–3419.CrossRefPubMed 33. Jones RA, Johnson VL, Hinton RH, Poirier GG, Chow SC, Kass GEN: Liver Poly(ADP-ribose)polymerase Is Resistant to Cleavage by Caspases. Biochem Biophys Res Commun 1999, 256: 436–441.CrossRefPubMed 34. Gobeil S, Boucher CC, Nadeau D, Poirier GG: Characterization

click here of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal BX-795 molecular weight proteases. Cell Death Diff 2001, 8: 588–594.CrossRef 35. Tait SWG, Green DR: Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008, 27: 6452–6461.CrossRefPubMed 36. Andrabi SA, Dawson TM, Dawson VL: Mitochondrial and Gemcitabine Nuclear Cross Talk in Cell Death: Parthanatos. Ann NY Acad Sci 2008, 1147: 233–241.CrossRefPubMed 37. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989, 49: 5870–5878.PubMed Competing interests The authors declare that they have no competing interests.

Authors’ contributions GR is the group leader and this work represents one of the research lines pursued in his laboratory; he directly supervised the experimental work. MC carried out most of the experimental work. GG and MC contributed with stimulating suggestions and encouraging discussions.”
“Background Lung cancers used to be categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). About 13%-15% of all lung cancers worldwide are SCLC. As a type of malignant tumor, SCLC shows many general clinical manifestations such as early metastasis, frequent recurrence and tendency toward poor response to chemotherapy. Some authors [1, 2] have previously demonstrated that these clinical manifestations are partially the result of a series of biological changes that occurred in tumor cells when responding to hypoxia. In other words, the hypoxic microenvironment promotes the malignant development of the tumor.